MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ndt/gfag067

Медицинская библиотека · Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026

Efficacy and safety of belimumab in IgA nephropathy: real-world evidence.

Wu Manyi, Cheng Yichun, Zhao Xingyang, Cai Xiaojing, Pan Chunyu, Qin Bowen, Zhao Hairui, Zhang Hui, Zhu Han, Zhou Qiaodan, Chang Xiaoyan, Liu Qingquan, Xiao Fang, Liu Xiaocheng, Ge Shuwang, Li Junhua, Xu Gang

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Belimumab, a monoclonal antibody targeting B lymphocyte stimulator, has shown benefits in systemic lupus erythematosus and lupus nephritis, but its role in IgA nephropathy (IgAN) remains unclear. We evaluated the effectiveness and safety of belimumab in IgAN.

METHODS

This retrospective cohort study included biopsy-proven IgAN patients at Tongji Hospital, China (July 2020-June 2024). 69 patients treated with belimumab were compared with 137 propensity score-matched controls receiving standard therapy. The primary outcome was proteinuria remission, defined as a reduction in 24-hour urinary protein excretion or urine protein-to-creatinine ratio (UPCR) to < 50% of baseline.

RESULTS

Among 206 patients with IgAN (median age 37 years, baseline eGFR 79 ml/min/1.73 m², proteinuria 1.1 g/24 h), 173 (84%) achieved proteinuria remission within 12 months. Remission was higher in the belimumab group: 59% vs 46% at 3 months, 77% vs 66% at 6 months, and 93% vs 80% at 12 months (P = 0.025 at 12 months), with lower time-averaged UPCR at 6 months [371 (248 738) vs.463(262 855) mg/g] and 12 months [360 (234 560) vs.433(243 720) mg/g, P = 0.066]. In newly diagnosed patients, remission was significantly higher at 3 months (76.5% vs. 47.1%, P = 0.009) and 6 months (88.2% vs. 67.6%, P = 0.045), with similar trends at later time points. In patients with baseline UPCR >600 mg/g and those receiving RAAS inhibitors, belimumab demonstrated comparable or superior proteinuria reduction. No excess of common adverse events was observed in the belimumab group.

CONCLUSION

Belimumab treatment was associated with higher proteinuria remission rates in patients with IgAN, without an increased incidence of common adverse events. These findings suggest that belimumab may represent a superior therapeutic approach for IgAN in real-world clinical practice.

Для цитирования: Wu Manyi, Cheng Yichun, Zhao Xingyang, Cai Xiaojing, Pan Chunyu, Qin Bowen, Zhao Hairui, Zhang Hui, Zhu Han, Zhou Qiaodan, Chang Xiaoyan, Liu Qingquan, Xiao Fang, Liu Xiaocheng, Ge Shuwang, Li Junhua, Xu Gang. Efficacy and safety of belimumab in IgA nephropathy: real-world evidence.. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2026. DOI: 10.1093/ndt/gfag067.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.